# Actuate Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/actuate-therapeutics

- Industry: Pharmaceuticals
- Headquarters: Fort Worth, US
- Website: www.actuatetherapeutics.com
- Total disclosed funding: $28M
- Latest round: Series B (Oct 1, 2019)
- Investors on record: 4

## About

Founded in 2015 and based in Texas, US, Actuate Therapeutics, Inc. is a biopharmaceutical company that engages in the research and development of compounds for the treatment of cancer and inflammatory diseases that lead to fibrosis and neurodegeneration. As of 2024, the company is headed by its CEO Daniel M. Schmitt. In August 2024, the firm raised USD 22.400 million in an IPO, selling 2.80 million shares at USD 8 per share, below the expected USD 8-10 range, on the Nasdaq Global Select Market under the ticker symbol "ACTU." Actuate Therapeutics, Inc. has granted the underwriters a 30-day option to purchase up to an additional 420,000 shares of common stock as part of the listing. Following the transaction, Bios Equity, and Kairos Venture retained a minority stake in Actuate Therapeutics, Inc., respectively.

Actuate's primary product, elraglusib, is a novel GSK-3 inhibitor that targets multiple molecular pathways associated with cancer growth and resistance. This drug is designed to address the limitations of traditional chemotherapy by inhibiting key immune checkpoints and regulating immune cell function. It provides cancer therapeutics with a focus on both tumor reduction and immune system modulation.

Actuate Therapeutics is in the research and development phase, with revenue primarily generated through investment and partnerships. The company is supported by funding from investors and collaborative agreements with academic and scientific organizations.

## Funding rounds

- Series B, Oct 1, 2019, $6.5M — DEFTA Partners, Bios Partners, Kairos Ventures
- Series B, May 17, 2019, $22M — DEFTA Partners, Bios Partners, Tech Coast Angels, Kairos Ventures

## Investors

- DEFTA Partners (https://capitalatlas.ai/funds/defta-partners) — Series B
- Bios Partners (https://capitalatlas.ai/funds/bios-partners) — Series B
- Tech Coast Angels — Series B
- Kairos Ventures (https://capitalatlas.ai/funds/kairos-ventures) — Series B